New treatment paradigms may offer advances in pancreatic cancer treatments
Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed
Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
CheckMate 77T demonstrates significantly improved event-free survival with neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab compared with chemotherapy and adjuvant placebo
The bispecific EGFR/MET-directed monoclonal antibody looks set to become the standard of care in this setting, but toxicity has to be managed carefully
Recently presented results suggest that a subset of patients with early stage rectal cancer could skip pre-operative radiotherapy, thus raising some questions about the standard of care
Extended analyses from two regulatory phase III trials show that the benefits of anti-PD-1-based therapy persist long term, even in patients with brain metastases
Additional exploratory analyses of the phase III CheckMate 816 trial reveal that event-free survival at 3 years is not influenced by surgical parameters and suggest that tumour inflammation may be a useful predictive biomarker
Side-effects may occur at unpredictable timepoints during a patient’s treatment journey and even after treatment cessation
Two early studies investigate the anticancer activity of derazantinib and RLY-4008 in patients with FGFR inhibitor-naïve cholangiocarcinoma
After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.